153 related articles for article (PubMed ID: 28549334)
21. Rational design of small-molecule inhibitors for β-catenin/T-cell factor protein-protein interactions by bioisostere replacement.
Yu B; Huang Z; Zhang M; Dillard DR; Ji H
ACS Chem Biol; 2013 Mar; 8(3):524-9. PubMed ID: 23272635
[TBL] [Abstract][Full Text] [Related]
22. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
23. Efficacy switching SAR of mGluR5 allosteric modulators: highly potent positive and negative modulators from one chemotype.
Sams AG; Mikkelsen GK; Brodbeck RM; Pu X; Ritzén A
Bioorg Med Chem Lett; 2011 Jun; 21(11):3407-10. PubMed ID: 21531137
[TBL] [Abstract][Full Text] [Related]
24. Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review.
Floresta G; Pistarà V; Amata E; Dichiara M; Marrazzo A; Prezzavento O; Rescifina A
Eur J Med Chem; 2017 Sep; 138():854-873. PubMed ID: 28738306
[TBL] [Abstract][Full Text] [Related]
25. Fragment-based Differential Targeting of PPI Stabilizer Interfaces.
Guillory X; Wolter M; Leysen S; Neves JF; Kuusk A; Genet S; Somsen B; Morrow JK; Rivers E; van Beek L; Patel J; Goodnow R; Schoenherr H; Fuller N; Cao Q; Doveston RG; Brunsveld L; Arkin MR; Castaldi P; Boyd H; Landrieu I; Chen H; Ottmann C
J Med Chem; 2020 Jul; 63(13):6694-6707. PubMed ID: 32501690
[TBL] [Abstract][Full Text] [Related]
26. The first small-molecule inhibitor of 14-3-3s: modulating the master regulator.
Kaiser M; Ottmann C
Chembiochem; 2010 Oct; 11(15):2085-7. PubMed ID: 20839267
[No Abstract] [Full Text] [Related]
27. State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist.
Baladi T; Abet V; Piguel S
Eur J Med Chem; 2015 Nov; 105():220-37. PubMed ID: 26498569
[TBL] [Abstract][Full Text] [Related]
28. Gaining insight into the catalysis by GH20 lacto-N-biosidase using small molecule inhibitors and structural analysis.
Hattie M; Ito T; Debowski AW; Arakawa T; Katayama T; Yamamoto K; Fushinobu S; Stubbs KA
Chem Commun (Camb); 2015 Oct; 51(81):15008-11. PubMed ID: 26312778
[TBL] [Abstract][Full Text] [Related]
29. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.
Sheng C; Dong G; Miao Z; Zhang W; Wang W
Chem Soc Rev; 2015 Nov; 44(22):8238-59. PubMed ID: 26248294
[TBL] [Abstract][Full Text] [Related]
30. Bromodomains and their pharmacological inhibitors.
Gallenkamp D; Gelato KA; Haendler B; Weinmann H
ChemMedChem; 2014 Mar; 9(3):438-64. PubMed ID: 24497428
[TBL] [Abstract][Full Text] [Related]
31. Design of libraries targeting protein-protein interfaces.
Fry D; Huang KS; Di Lello P; Mohr P; Müller K; So SS; Harada T; Stahl M; Vu B; Mauser H
ChemMedChem; 2013 May; 8(5):726-32. PubMed ID: 23436619
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic potential of leptin receptor modulators.
Leggio A; Catalano S; De Marco R; Barone I; Andò S; Liguori A
Eur J Med Chem; 2014 May; 78():97-105. PubMed ID: 24681069
[TBL] [Abstract][Full Text] [Related]
33. Structure-based design of HSPA5 inhibitors: from peptide to small molecule inhibitors.
Huang M; Li Z; Li D; Walker S; Greenan C; Kennedy R
Bioorg Med Chem Lett; 2013 May; 23(10):3044-50. PubMed ID: 23562057
[TBL] [Abstract][Full Text] [Related]
34. Membrane anchoring γ-secretase modulators with terpene-derived moieties.
Naumann EC; Göring S; Ogorek I; Weggen S; Schmidt B
Bioorg Med Chem Lett; 2013 Jul; 23(13):3852-6. PubMed ID: 23707256
[TBL] [Abstract][Full Text] [Related]
35. Fragment-Based Stabilizers of Protein-Protein Interactions through Imine-Based Tethering.
Wolter M; Valenti D; Cossar PJ; Levy LM; Hristeva S; Genski T; Hoffmann T; Brunsveld L; Tzalis D; Ottmann C
Angew Chem Int Ed Engl; 2020 Nov; 59(48):21520-21524. PubMed ID: 32816380
[TBL] [Abstract][Full Text] [Related]
36. Small-molecule PARP modulators--current status and future therapeutic potential.
Penning TD
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):577-86. PubMed ID: 20812149
[TBL] [Abstract][Full Text] [Related]
37. A structural rationale for selective stabilization of anti-tumor interactions of 14-3-3 proteins by cotylenin A.
Ottmann C; Weyand M; Sassa T; Inoue T; Kato N; Wittinghofer A; Oecking C
J Mol Biol; 2009 Mar; 386(4):913-9. PubMed ID: 19244612
[TBL] [Abstract][Full Text] [Related]
38. Application of encoded library technology (ELT) to a protein-protein interaction target: discovery of a potent class of integrin lymphocyte function-associated antigen 1 (LFA-1) antagonists.
Kollmann CS; Bai X; Tsai CH; Yang H; Lind KE; Skinner SR; Zhu Z; Israel DI; Cuozzo JW; Morgan BA; Yuki K; Xie C; Springer TA; Shimaoka M; Evindar G
Bioorg Med Chem; 2014 Apr; 22(7):2353-65. PubMed ID: 24593905
[TBL] [Abstract][Full Text] [Related]
39. Dendrimer space exploration: an assessment of dendrimers/dendritic scaffolding as inhibitors of protein-protein interactions, a potential new area of pharmaceutical development.
Mignani S; El Kazzouli S; Bousmina MM; Majoral JP
Chem Rev; 2014 Jan; 114(2):1327-42. PubMed ID: 24127777
[No Abstract] [Full Text] [Related]
40. Inhibitors of Ras-SOS Interactions.
Lu S; Jang H; Zhang J; Nussinov R
ChemMedChem; 2016 Apr; 11(8):814-21. PubMed ID: 26630662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
